Abbott Laboratories Reports Solid Q1 2024 Results with Strong Growth and Strategic Advancements

Abbott Laboratories Q1 2024 Earnings Call Highlights

Abbott Laboratories reported first-quarter adjusted earnings per share of $0.98, exceeding analyst estimates. The company raised its full-year guidance ranges, showcasing continued momentum and growth across its diversified portfolio.

Financial Results and Outlook

• Organic sales growth of 4.7% in Q1 2024
• Full-year adjusted EPS forecast raised to $4.55-$4.70
• Organic sales growth range adjusted to 8.5%-10%

Strategic Advancements and Product Performance

1. Significant growth in medical devices, diagnostics, and established pharmaceuticals
2. Continuous product approvals and clinical milestones achievement
3. Expansion opportunities in medical device segments, including structural heart and diabetics care

Abbott Laboratories demonstrates strong growth, strategic advancements, and a competitive advantage in the healthcare market, positioning the company for continued success and innovation.